SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Realignment of Bond Repayments

5 Nov 2018 07:00

RNS Number : 2667G
Collagen Solutions PLC
05 November 2018
 

5 November 2018

 

Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")

 

Realignment of Bond Repayments to enable further growth to be achieved

Delivering on our Growth Strategy

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a deed of variation to its existing Bond Subscription Agreement with Norgine Ventures. This variation provides for a 6month principal repayment holiday. While there is no current year requirement for this variation, it will provide management with greater flexibility to exploit growth opportunities for future years.

 

Consistent with the Company's ability to conservatively manage its cash balances whilst looking to exploit growth opportunities for the benefit of shareholders the Company has agreed an amendment to the timing of principal repayments on Tranche A and Tranche B Bonds issued to Norgine Ventures under the 2017 Bond Subscription Agreement. The variation gives a principal repayment holiday of six months from 31st October 2018 to 31st March 2019 with the principal repayments being instead made via a balloon payment at the redemption of the Bonds on 30 September 2020 for Tranche A and 31 January 2021 for Tranche B. Prior to this agreement, the Company remained in compliance with all payment schedules and had repaid a total of £0.42million in principal against the total £3 million drawn.

 

Commenting on outlook, Hilary Spence, CFO says: "We have seen a return to growth in the first six months of the financial year and we remain on track to meet our financial performance objectives in line with market expectations. The management team has continued to generate a large number of business leads, some of which may require incremental upfront investment on initiation. Whilst there is no current financial year requirement, with one eye on exploiting opportunities for future financial years this variation provides management greater flexibility to deliver on these leads and on other growth opportunities that will contribute to future performance."

 

 

Enquiries:

Collagen Solutions Plc

 

Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO

 

 

 

Cenkos Securities Plc (Nominated Adviser and Broker)

 

Steve Cox (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

Mob: 07841 917 679

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBBBDBISGBGIS
Date   Source Headline
12th Sep 20167:00 amRNSIssue of Equity
24th Aug 201611:26 amRNSResult of AGM
25th Jul 201611:48 amRNSPosting of Annual Report
19th Jul 20167:15 amRNSHardman research: Focused scalable growth
15th Jul 20167:00 amRNSGrant of Options
12th Jul 20165:12 pmRNSDirector/PDMR Shareholding
12th Jul 201611:51 amRNSHolding(s) in Company
11th Jul 20164:15 pmRNSDirector/PDMR Shareholding
11th Jul 20163:16 pmRNSDirector/PDMR Shareholding
11th Jul 20167:00 amRNSFinal Results
13th Jun 20167:00 amRNSNotice of Results Investor Presentation
4th May 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSLeadership changes and preliminary FY revenue
27th Apr 20165:34 pmRNSHolding(s) in Company
26th Apr 20168:28 amRNSJoint Venture Agreement in China
19th Apr 20167:00 amRNSSupply of collagen materials to Merck
30th Mar 20169:37 amRNSHolding(s) in Company
23rd Mar 20167:00 amRNSResearch collaboration
26th Feb 20161:02 pmRNSHolding(s) in Company
12th Feb 20167:00 amRNSDeath of adviser
3rd Feb 20167:00 amRNSCollagen Solutions present at The Scotsman
22nd Jan 20165:47 pmRNSHolding(s) in Company
21st Jan 201610:14 amRNSChairman's Share Purchase
20th Jan 20167:00 amRNSTrading Update
14th Jan 20165:29 pmRNSHolding(s) in Company
9th Dec 201511:17 amRNSHolding(s) in Company
9th Dec 20157:00 amRNSHardman Issues Research Report
7th Dec 20157:00 amRNSCollagen Solutions Supply Agreement with BBI
2nd Dec 20153:48 pmRNSDirector/PDMR Shareholding
1st Dec 20157:00 amRNSHalf Yearly Report
20th Nov 20153:20 pmRNSDeath of a Director
18th Nov 20157:00 amRNSAppointment of Chief Business Officer
3rd Nov 20157:00 amRNSNotice of Results
28th Sep 20157:00 amRNSCollagen supply agreement to Yucel Medical
22nd Sep 20157:00 amRNSMedical Research Studentship
16th Sep 20157:00 amRNSSupply Agreement with Histogenics Corporation
14th Sep 20157:00 amRNSAcquisition of a regenerative medicine product
3rd Sep 20157:00 amRNSFDA approval for NovaBone product
28th Aug 201510:11 amRNSAGM Statement
28th Aug 20157:00 amRNSJoins consortium developing new treatments
22nd Jul 20157:00 amRNSPosting of Annual Report & Notice of AGM
15th Jul 201510:09 amRNSHardman & Co issues research on Collagen Solutions
14th Jul 20157:00 amRNSPartnership with UCL and Oxford MEStar Ltd
13th Jul 20157:00 amRNSFinal Results
3rd Jul 20152:11 pmRNSNotice of Results
26th Jun 20157:00 amRNSChange of Adviser
22nd Jun 20157:00 amRNSInnovate UK Grant Award
28th May 20157:00 amRNSNew Patent Granted
17th Apr 20151:53 pmRNSHardman & Co issues research report
14th Apr 20157:00 amRNSUK Investor Show attendance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.